0001628280-26-008545
SEC filingEscalon Medical Corp. reported modest profitability for Q2 2026 (period ending December 31, 2025) with net revenues of $3.6 million and net income applicable to common stockholders of $44,000. The company generated operating income of $99,000 from operations, though net cash used in operating activities was -$432,000. Key financial drivers included gross profit of $1.6 million (calculated from $3.6M revenue minus $2.0M cost of goods sold) and effective cost management with total costs and expenses of $3.5 million. The balance sheet shows total assets of $5.0 million with shareholders' equity of $1.8 million, though cash decreased by $465,000 during the quarter to $337,000. No prior period comparisons are provided in the data, limiting trend analysis.
Escalon Medical Corp. reported Q2 2026 financial results for the period ending December 31, 2025. The company achieved net revenues of $3.6 million with cost of product and service sold of $2.0 million, resulting in gross profit of $1.6 million. Operating expenses totaled $1.431 million ($1.3M marketing/general/administrative plus $131K R&D), leading to income from operations of $99,000. After other expenses of -$1,000 and no income tax expense, net income was $98,000. Net income applicable to common stockholders was $44,000 after allocations to participating securities and convertible preferred stocks. No prior period comparisons are provided in the data, limiting analysis of trends.
Revenue analysis is limited as the filing provides only consolidated revenue figures without segment breakdown, geographic mix, or specific growth drivers. The company reported net revenues of $3.6 million with no disclosure of revenue by product line, service category, or geographic region. The XBRL data shows revenue as a single consolidated figure without dimensional breakdowns. No information is provided about revenue concentration, customer diversification, or specific products/services driving performance.
The company achieved a gross margin of 44.4% based on $1.6 million gross profit from $3.6 million revenue. Operating margin was 2.8% with operating income of $99,000. Cost structure shows marketing, general and administrative expenses of $1.3 million (36.1% of revenue) and research and development expenses of $131,000 (3.6% of revenue). Total costs and expenses were $3.5 million, representing 97.2% of revenue. The company maintained profitability despite relatively high operating expenses relative to revenue.
Cash flow from operations was negative at -$432,000, primarily due to changes in working capital including a $673,000 increase in accounts receivable and -$618,000 increase in inventories. Investing activities used -$4,000 for equipment purchases, while financing activities used -$28,000 for debt repayments. Cash decreased by $465,000 during the quarter to $337,000. The balance sheet shows total assets of $5.0 million with current assets of $4.3 million (including $2.2M net accounts receivable and $1.5M inventory). Total liabilities are $3.2 million with current liabilities of $2.6 million, resulting in shareholders' equity of $1.8 million.
The filing provides no forward-looking statements, management guidance, strategic priorities, or specific risk factors. No information is disclosed about future expectations, projected performance, planned initiatives, or market outlook. The document contains only historical financial data without commentary on future plans, growth strategies, or anticipated challenges. Investors must rely solely on the reported historical results without management perspective on future direction.